News

CuraGen’s phase I/II trial, evaluating CR011-vcMMAE for the treatment of advanced breast cancer, has met the efficacy criteria for advancement to the second stage of enrollment. CR011-vcMMAE is

Watson Pharmaceuticals has entered into a definitive agreement to acquire Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in

Antigenics has announced the launch of phase-III trial for malaria vaccine, RTS,S by GlaxoSmithKline, which contains Antigenics’ QS-21 Stimulon adjuvant. Phase-II malaria studies showed that, over an eight-month

Xanodyne has received approval from the FDA for Zipsor (diclofenac potassium) Liquid Filled Capsules, to treat mild-to-moderate acute pain in adults. The recommended daily dose of diclofenac potassium

NxStage’ subsidiary, Medisystems has signed a five year distribution agreement with Gambro. Under the agreement, Medisystems will supply blood tubing sets, including the ReadySet and the Streamline to

Canada-based Neuromed has sold the US rights of its investigational drug candidate, Exalgo (hydromorphone HCl), an extended-release tablets, to Covidien’s subsidiary, Mallinckrodt. Neuromed has received a one-time upfront

Access has signed evaluation agreements with two biopharmaceutical companies, for its Cobalamin oral drug delivery technology. Cobalamin technology utilizes the body’s natural vitamin B12 oral uptake mechanism to

Epeius’ Rexin-G has been granted FDA’ fast track designation, for use as a second-line treatment for advanced or metastatic pancreatic cancer. The designation is granted following a critical

GlaxoSmithKline and Genmab have announced that the FDA has informed the companies that the agency has extended the action date for the ofatumumab BLA application by three months.